RDRachita Dhurat

Rachita Dhurat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rachita Dhurat has a total of 144 co-authors. Here are the top co-authors by number of shared publications:

  • Richa Sharma

    Department of Dermatology, Mahatma Gandhi Mission Medical College and Hospital, Vashi, Navi Mumbai, Maharashtra, India

    20 shared publications
  • Aseem Sharma

    Skin Saga Centre for Dermatology Mumbai India

    8 shared publications
  • Sandip Agrawal

    Department of Dermatology, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, India

    6 shared publications
  • Priyanka Kowe

    Department of Dermatology, Venereology and Leprosy, Lokmanya Tilak Municipal Medical College and Government Hospital, Sion, Mumbai, Maharashtra, India

    5 shared publications
  • Archi Ranka

    Department of Dermatology, Gujarat Medical Education and Research Society Medical College, Gandhinagar, Gujarat, India

    4 shared publications
  • Kiran Chahal

    Department of Dermatology, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, Maharashtra, India

    4 shared publications

Latest Publications

  • Open Access

    Bicalutamide: A potential new oral anti-androgenic drug for female pattern hair loss - A case series

    by Richa Sharma, Rachita S Dhurat, Grishma Kale, Harini Prasanna

    Female pattern hair loss (FPHL) is a common cause of progressive hair thinning in women and can be difficult to manage in those with inadequate response to standard therapies. This case series evaluates the efficacy and safety of oral bicalutamide as an adjunct to low-dose oral minoxidil (LDOM) in women with FPHL refractory to minoxidil monotherapy. Thirty women with clinically and trichoscopically confirmed FPHL (Sinclair grade ≥2) who showed no significant improvement after more than six months of LDOM were included. Oral bicalutamide was added at 50 mg twice weekly for one month, then increased to 50 mg on alternate days with regular biochemical monitoring. Response was assessed at six months using standardized photographs and a 7-point rating scale. At six months, 63.3% showed slight improvement and 33.3% moderate improvement; one patient had no change. No adverse effects were observed. Larger prospective studies are needed to confirm long-term safety and efficacy.

  • Open Access

    Is tapering and stopping of tofacitinib possible among pediatric and adolescent alopecia areata patients?

    by Rachita S Dhurat, Richa Sharma, Archi Ranka, Grishma Kale

    Is tapering and stopping of tofacitinib possible among pediatric and adolescent alopecia areata patients?

  • Hair Care in Pregnancy

    by Rachita Dhurat, Richa Sharma

  • Open Access

    Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations

    by Rodney Sinclair, Chao‐Chun Yang, Wen‐Hung Chung, Rachita Dhurat, Anil Ganjoo, Saranya Khunkhet, Jinran Lin, Anchala Parthasaradhi, Hyun‐Tae Shin, Kihyuk Shin, et al.

    Background: Alopecia areata (AA) affects all ages, genders, and ethnicities. AA severely impacts patients' quality of life. Treatments indicated for AA have only been approved since 2022/2023. While some Asia Pacific (APAC) countries/regions have national or regional guidelines, many lack AA‐specific guidance or have not updated existing guidelines to incorporate recently approved treatments. Methods: To better inform treatment decisions, 18 dermatologists from Australia, China, India, Korea, Malaysia, Singapore, Taiwan, and Thailand completed a three‐round Delphi‐based consensus process involving survey completion, open discussion, and statement voting. A consensus for Likert‐type and multiple‐choice statements was defined as ≥ 70% agreement or disagreement. Results: Consensus was achieved on 140 statements. The panel recognizes that AA is clinically heterogeneous and imposes a considerable burden on patients and their families. Trichoscopy is deemed essential for diagnosing and monitoring AA, while skin biopsy is reserved for when the cause of hair loss is unclear. In terms of disease severity, moderate AA is defined as 21%–49% hair loss and severe AA as ≥ 50% hair loss. Regarding treatment, topical corticosteroids are recommended in children < 12 years. For patients aged ≥ 12 years, topical and intralesional corticosteroids could be used for mild‐to‐moderate AA, while Janus kinase inhibitors and systemic corticosteroids have a role in moderate‐to‐severe AA. Adjuvant minoxidil could also be used in chronic AA. Conclusions: This modified Delphi‐based consensus provides a practical, region‐focused framework to standardize the diagnosis and management of AA across diverse APAC healthcare settings in hope of improving patient outcomes.


  • Open Access

    Synergistic therapeutic effect of systemic steroids and dithranol in a patient of alopecia totalis—A case report

    by Rachita S. Dhurat, Richa Sharma

    Alopecia areata (AA) is an autoimmune disorder characterized by patchy, non-scarring hair loss. Anthralin (dithranol) is a topical irritant that has shown efficacy in treating AA. Despite its therapeutic potential, there is a common belief that combining steroids with dithranol may reduce its effectiveness. This report presents a case of alopecia totalis in which a combination of systemic steroids and dithranol was used with a synergistic therapeutic effect. A 12-year-old boy with a six-month history of complete scalp hair loss was diagnosed with alopecia totalis. He was treated with betamethasone pulse therapy and Derobin TM ointment (a combination of coal tar, salicylic acid, and dithranol) and applied to both halves of the scalp on a rotational basis. The patient misunderstood the instructions, applying the ointment only to one side while taking systemic steroids. After 2 months, hair regrowth was observed exclusively on the treated side, demonstrating the potential synergistic effect of the combined treatment. Anthralin promotes hair regrowth by inhibiting pro-inflammatory cytokines, while steroids also reduce these cytokines, suggesting a possible synergistic effect. Our case highlights that combining systemic steroids with dithranol can reduce irritation, improve compliance, and enhance hair regrowth. The findings suggest that this combination could be effective for managing severe AA with minimal side effects. The combination of dithranol and systemic steroids may offer a promising approach to treating alopecia areata, enhancing regrowth while minimizing irritation.

  • Open Access

    Inherited reactive perforating collagenosis – A rare entity

    by Archi Ranka, M. V. Chethan, Richa Sharma, Rachita S. Dhurat

    Reactive perforating collagenosis (RPC) is a rare primary perforating dermatosis, showing distinct transepidermal elimination of modified collagen across the epidermis. This condition typically appears in two forms: Hereditary variant (rare) and acquired variant. Patients present with pruritic hyperkeratotic papules with central crusting mainly over extensor areas of extremities and hands, most likely over areas of superficial trauma with vertically oriented collagen fibers on histopathology. Here, we present a case of hereditary variant of RPC with classic histopathological findings confirmed with special stains.

  • Open Access

    COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists

    by Cathal O'COnnor, Aoife Boyle, Leila Asfour, Bevin Bhoyrul, Laita Bokhari, George Cotsarelis, Chantal Cotter, Brittany Craiglow, Lara Cutlar, Rachita Dhurat, et al.

    Background: Alopecia areata (AA) is a common non‐scarring alopecia. Data continue to emerge on associations with autoimmune and other conditions. Janus kinase inhibitors (JAKi) are increasingly used to treat AA.Objectives: The aim was to assess variation in laboratory testing in patients with AA among hair experts internationally and to compare subspecialized clinical practice to current guidelines.Methods: Thirty hair experts from 14 countries and six continents contributed to develop a 24‐item survey collecting demographic information on respondents; methods of severity assessment; and laboratory testing practices in AA for mimics, contributory factors, associations, and workup for systemic therapy. The survey was distributed to a global network of expert hair specialists.Results: Of 214 respondents, 79.9% (171/214) had special interest/expertise in hair loss disorders, and 35.5% (n = 76) were based in Europe. Most cared for both adults and children (87.9%, n = 188). For clinical assessment, almost two‐thirds (63.6%, n = 136) used the Severity of Alopecia Tool and 38% (n = 84) used the Dermatology Life Quality Index. Only 24.3% (n = 52) typically tested for alternative infectious or inflammatory diagnoses, 39.7% (n = 85) typically tested for contributory conditions such as nutritional deficiencies, and 50.9% (n = 109) typically tested for co‐existent autoimmune illnesses. Thyroid function testing was routinely performed in 73.4% (n = 157) and complete blood count (CBC) was checked in 65.9% (n = 141). Compared to conventional systemic therapy, experts were more likely to check lipid levels, creatine kinase, coagulation profiles, thrombophilia screens, tuberculosis blood testing, hepatitis B and C serology before prescribing JAKi.Conclusions: Real world practice of laboratory testing for AA by hair experts, who may see more severe or complex alopecia, is variable. Most experts routinely perform thyroid function and CBC testing. We discuss evidence for indications for testing for AA mimics, contributory factors, associated autoimmune conditions, and before systemic therapy. Further research is required to characterise the role of laboratory testing in AA.


  • Open Access

    Real‐World Efficacy and Safety of Cuticapil Stem Hair Serum as an Add‐On to Minoxidil in Androgenetic Alopecia: A Prospective Observational Study

    by Rachita Dhurat, Girish R. Kulkarni, Anil Ganjoo, Manjul Agarwal, Pradeep Kumari, Pradyuman Vaidya, Sumit Gupta, Shankar Savant, Rathish Nair, Mahima Agarwal, et al.

    Background: Androgenetic alopecia (AGA) is a common age‐related hair loss condition influenced by genetics and androgen activity. Aim: This study evaluated the safety and efficacy of Cuticapil Stem Hair Serum in improving hair loss in AGA patients. Method: This multicenter, prospective, observational study assessed the real‐world efficacy and safety of Cuticapil Stem Hair Serum in patients with androgenetic alopecia. A total of 60 subjects were evaluated, with the Cuticapil and Standard of Care groups compared using the Mann–Whitney and Wilcoxon signed‐rank tests. Key assessments included the hair pull test, global photographic analysis, and hair shedding count. No adverse events were reported, reinforcing the serum's favorable safety profile. Result: The Cuticapil + SoC treatment group consistently showed higher mean ranks across multiple parameters compared to the SoC‐only group. The addition of Cuticapil Serum to SoC significantly reduced hair shedding ( p = 0.0220). In the Hair Pull Test, the Cuticapil + SoC group had a lower mean rank (26.97) than SoC alone (34.03) ( p = 0.0196), indicating greater efficacy. Global photography analysis showed a higher mean rank of 36.13 in the Cuticapil + SoC group compared to 24.87 in the SoC group ( p = 0.0057), further supporting its effectiveness. Conclusion: Cuticapil Stem Hair Serum, when used in addition to standard care, significantly enhances hair growth and reduces hair fall in patients with mild to moderate Androgenetic Alopecia and Female Pattern Hair Loss. It showed superior results in promoting hair growth, reducing shedding, improving hair density, appearance, and managing hair loss.

  • Open Access

    Pseudorheumatoid nodules in a young woman

    by Priyanka Kowe, Pooja Manohar Golwad, K R Prajwal Srivatsa, Rachita S Dhurat